The post-Davos influx of foreign investment appears to be arriving more quickly than expected, starting with German drugmaker Stada‘s purchase of Argentine generics producer Vannier.
The post-Davos influx of foreign investment appears to be arriving more quickly than expected, starting with German drugmaker Stada‘s purchase of Argentine generics producer Vannier. See website.
The transaction, completed this month, was valued at $13 million. See press release.
Analysts say more transactions of this type can be expected as foreign buyers begin to set their sights on Argentine companies that were left weakened by the previous government’s price controls.
In recent years, the Argentine government imposed strict price controls on medicines, while skyrocketing inflation left drugmakers having to absorb increased costs.
The acquisition of Vannier is Stada’s first foray into Latin America, but it is believed that the German generics specialist intends to expand in the region. It will use Vannier to introduce its own OTC products to the local market.
Vannier specialises in producing solids, and has a plant in the Buenos Aires neighbourhood of Barracas.
The company, which belonged to the Mosner family has annual sales of €7 million and employs close to 100 people.
